U.S. markets closed

Investors Who Bought Oxford Immunotec Global (NASDAQ:OXFD) Shares A Year Ago Are Now Down 22%

Simply Wall St

Investors can approximate the average market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. Unfortunately the Oxford Immunotec Global PLC (NASDAQ:OXFD) share price slid 22% over twelve months. That falls noticeably short of the market return of around 7.9%. However, the longer term returns haven't been so bad, with the stock down 13% in the last three years. It's down 25% in about a quarter. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.

See our latest analysis for Oxford Immunotec Global

Oxford Immunotec Global isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Oxford Immunotec Global grew its revenue by 23% over the last year. That's definitely a respectable growth rate. Meanwhile, the share price is down 22% over twelve months, which is disappointing given the progress made. This implies the market was expecting better growth. But if revenue keeps growing, then at a certain point the share price would likely follow.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

NasdaqGM:OXFD Income Statement, March 9th 2020

This free interactive report on Oxford Immunotec Global's balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

Oxford Immunotec Global shareholders are down 22% for the year, but the market itself is up 7.9%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 2.4% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 2 warning signs for Oxford Immunotec Global that you should be aware of.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.